DK173724B1 - Analysemetode og diagnosesæt til undersøgelse af unormal lipidmetabolisme - Google Patents

Analysemetode og diagnosesæt til undersøgelse af unormal lipidmetabolisme Download PDF

Info

Publication number: DK173724B1
Authority: DK; Denmark
Prior art keywords: apo; lipoprotein; solid; bound; molecules
Prior art date: 1986-09-29

Application number

DK198705092A

Other languages

Danish (da)

English (en)

Other versions

DK509287D0 (da

DK509287A (da

Inventor

Steven Young

Richard S Smith

Linda K Curtiss

Doreen M Hogle

Joseph L Witztum

Original Assignee

Scripps Clinic Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-09-29

Filing date

1987-09-28

Publication date

2001-07-30

1987-09-28 Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res

1987-09-28 Publication of DK509287D0 publication Critical patent/DK509287D0/da

1988-03-30 Publication of DK509287A publication Critical patent/DK509287A/da

2001-07-30 Application granted granted Critical

2001-07-30 Publication of DK173724B1 publication Critical patent/DK173724B1/da

Links

238000004458 analytical method Methods 0.000 title claims description 36
230000002159 abnormal effect Effects 0.000 title claims description 21
230000037356 lipid metabolism Effects 0.000 title claims description 21
238000009007 Diagnostic Kit Methods 0.000 title description 2
102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract description 150
108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract description 148
108010008150 Apolipoprotein B-100 Proteins 0.000 claims abstract description 121
238000000034 method Methods 0.000 claims abstract description 61
210000004408 hybridoma Anatomy 0.000 claims abstract description 56
102000006991 Apolipoprotein B-100 Human genes 0.000 claims abstract description 21
239000007790 solid phase Substances 0.000 claims description 103
239000000203 mixture Substances 0.000 claims description 61
108090000623 proteins and genes Proteins 0.000 claims description 53
102000004190 Enzymes Human genes 0.000 claims description 51
102000004169 proteins and genes Human genes 0.000 claims description 50
108090000790 Enzymes Proteins 0.000 claims description 49
239000007791 liquid phase Substances 0.000 claims description 49
239000007787 solid Substances 0.000 claims description 48
238000003556 assay Methods 0.000 claims description 46
239000007788 liquid Substances 0.000 claims description 42
210000004369 blood Anatomy 0.000 claims description 40
239000008280 blood Substances 0.000 claims description 40
102000004895 Lipoproteins Human genes 0.000 claims description 33
108090001030 Lipoproteins Proteins 0.000 claims description 33
238000002156 mixing Methods 0.000 claims description 26
239000011159 matrix material Substances 0.000 claims description 19
238000004166 bioassay Methods 0.000 claims description 15
238000012423 maintenance Methods 0.000 claims description 13
239000003550 marker Substances 0.000 claims description 10
230000009871 nonspecific binding Effects 0.000 claims description 10
238000011282 treatment Methods 0.000 claims description 8
230000008569 process Effects 0.000 claims description 6
239000000376 reactant Substances 0.000 claims description 5
238000003756 stirring Methods 0.000 claims description 4
101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 claims description 3
230000008021 deposition Effects 0.000 claims description 3
101000733802 Homo sapiens Apolipoprotein A-I Proteins 0.000 claims 2
102000052249 human APOB Human genes 0.000 claims 2
238000002965 ELISA Methods 0.000 abstract description 29
102100040202 Apolipoprotein B-100 Human genes 0.000 description 99
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 98
108010010234 HDL Lipoproteins Proteins 0.000 description 78
102000015779 HDL Lipoproteins Human genes 0.000 description 78
239000000523 sample Substances 0.000 description 72
108010007622 LDL Lipoproteins Proteins 0.000 description 58
102000007330 LDL Lipoproteins Human genes 0.000 description 58
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 50
239000002953 phosphate buffered saline Substances 0.000 description 50
235000018102 proteins Nutrition 0.000 description 47
229940088598 enzyme Drugs 0.000 description 45
235000012000 cholesterol Nutrition 0.000 description 42
230000027455 binding Effects 0.000 description 39
208000029078 coronary artery disease Diseases 0.000 description 39
239000000427 antigen Substances 0.000 description 35
108091007433 antigens Proteins 0.000 description 35
102000036639 antigens Human genes 0.000 description 35
102000007592 Apolipoproteins Human genes 0.000 description 32
108010071619 Apolipoproteins Proteins 0.000 description 32
239000002245 particle Substances 0.000 description 30
206010003445 Ascites Diseases 0.000 description 29
210000004027 cell Anatomy 0.000 description 29
210000002966 serum Anatomy 0.000 description 28
150000002632 lipids Chemical class 0.000 description 23
108010001336 Horseradish Peroxidase Proteins 0.000 description 21
239000003153 chemical reaction reagent Substances 0.000 description 21
230000000890 antigenic effect Effects 0.000 description 20
238000002360 preparation method Methods 0.000 description 19
108010004103 Chylomicrons Proteins 0.000 description 18
239000012530 fluid Substances 0.000 description 18
238000010790 dilution Methods 0.000 description 17
239000012895 dilution Substances 0.000 description 17
108010062497 VLDL Lipoproteins Proteins 0.000 description 15
238000003127 radioimmunoassay Methods 0.000 description 15
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 14
241000282414 Homo sapiens Species 0.000 description 13
239000000872 buffer Substances 0.000 description 13
239000000463 material Substances 0.000 description 13
102000018616 Apolipoproteins B Human genes 0.000 description 12
108010027006 Apolipoproteins B Proteins 0.000 description 12
239000011521 glass Substances 0.000 description 12
201000001320 Atherosclerosis Diseases 0.000 description 11
108010032595 Antibody Binding Sites Proteins 0.000 description 10
210000004185 liver Anatomy 0.000 description 10
239000000243 solution Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 9
230000028993 immune response Effects 0.000 description 9
239000012071 phase Substances 0.000 description 9
239000000758 substrate Substances 0.000 description 9
150000003626 triacylglycerols Chemical class 0.000 description 9
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
238000005259 measurement Methods 0.000 description 8
239000004793 Polystyrene Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
230000006870 function Effects 0.000 description 7
230000003287 optical effect Effects 0.000 description 7
229920002223 polystyrene Polymers 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
101800001976 Apolipoprotein B-48 Proteins 0.000 description 6
102400000352 Apolipoprotein B-48 Human genes 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
108060003951 Immunoglobulin Proteins 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
206010035226 Plasma cell myeloma Diseases 0.000 description 6
229920001213 Polysorbate 20 Polymers 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000007423 decrease Effects 0.000 description 6
239000012153 distilled water Substances 0.000 description 6
230000008105 immune reaction Effects 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
102000018358 immunoglobulin Human genes 0.000 description 6
238000001155 isoelectric focusing Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
201000000050 myeloid neoplasm Diseases 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
239000000047 product Substances 0.000 description 6
238000003860 storage Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
229920000936 Agarose Polymers 0.000 description 5
102000009081 Apolipoprotein A-II Human genes 0.000 description 5
108010087614 Apolipoprotein A-II Proteins 0.000 description 5
238000008214 LDL Cholesterol Methods 0.000 description 5
102000000853 LDL receptors Human genes 0.000 description 5
108010001831 LDL receptors Proteins 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
-1 cholesterol Chemical class 0.000 description 5
230000002860 competitive effect Effects 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
235000005911 diet Nutrition 0.000 description 5
230000037213 diet Effects 0.000 description 5
238000005755 formation reaction Methods 0.000 description 5
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
239000002243 precursor Substances 0.000 description 5
238000011002 quantification Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
102000006410 Apoproteins Human genes 0.000 description 4
108010083590 Apoproteins Proteins 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
102000003992 Peroxidases Human genes 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000036046 immunoreaction Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
108040007629 peroxidase activity proteins Proteins 0.000 description 4
239000004800 polyvinyl chloride Substances 0.000 description 4
229920000915 polyvinyl chloride Polymers 0.000 description 4
235000004252 protein component Nutrition 0.000 description 4
238000003118 sandwich ELISA Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000283707 Capra Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000004366 Glucose oxidase Substances 0.000 description 3
108010015776 Glucose oxidase Proteins 0.000 description 3
208000017170 Lipid metabolism disease Diseases 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 3
108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 3
241000473945 Theria <moth genus> Species 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
239000007982 barbital buffer Substances 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000009534 blood test Methods 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000003599 detergent Substances 0.000 description 3
239000013024 dilution buffer Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
239000012847 fine chemical Substances 0.000 description 3
239000011888 foil Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
229940116332 glucose oxidase Drugs 0.000 description 3
235000019420 glucose oxidase Nutrition 0.000 description 3
230000000951 immunodiffusion Effects 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
238000007373 indentation Methods 0.000 description 3
230000004576 lipid-binding Effects 0.000 description 3
238000004811 liquid chromatography Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
108010023302 HDL Cholesterol Proteins 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
108010028554 LDL Cholesterol Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000005717 Myeloma Proteins Human genes 0.000 description 2
108010045503 Myeloma Proteins Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
150000001840 cholesterol esters Chemical class 0.000 description 2
238000005352 clarification Methods 0.000 description 2
239000004927 clay Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
230000004927 fusion Effects 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
108010022197 lipoprotein cholesterol Proteins 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
230000000444 normolipidemic effect Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
238000002731 protein assay Methods 0.000 description 2
239000012460 protein solution Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000000472 traumatic effect Effects 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000005199 ultracentrifugation Methods 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
102000057234 Acyl transferases Human genes 0.000 description 1
108700016155 Acyl transferases Proteins 0.000 description 1
101710095342 Apolipoprotein B Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101100328078 Bos taurus CL46 gene Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
206010014476 Elevated cholesterol Diseases 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
206010071602 Genetic polymorphism Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229910003556 H2 SO4 Inorganic materials 0.000 description 1
108091005886 Hemoglobin subunit gamma Proteins 0.000 description 1
102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
108010046315 IDL Lipoproteins Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
101710105047 Lipoprotein B Proteins 0.000 description 1
238000003231 Lowry assay Methods 0.000 description 1
238000009013 Lowry's assay Methods 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
102000054727 Serum Amyloid A Human genes 0.000 description 1
101710190759 Serum amyloid A protein Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
235000006468 Thea sinensis Nutrition 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
238000000333 X-ray scattering Methods 0.000 description 1
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000489 anti-atherogenic effect Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
230000027645 antigenic variation Effects 0.000 description 1
108010059336 apolipoprotein B-26 Proteins 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
239000011324 bead Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
235000015123 black coffee Nutrition 0.000 description 1
235000020279 black tea Nutrition 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000006790 cellular biosynthetic process Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
239000011365 complex material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000012953 feeding on blood of other organism Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
230000004545 gene duplication Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002621 immunoprecipitating effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000008604 lipoprotein metabolism Effects 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
235000020925 non fasting Nutrition 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
238000000053 physical method Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000009862 primary prevention Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000012857 radioactive material Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000001448 refractive index detection Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Measuring And Recording Apparatus For Diagnosis (AREA)
Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Fats And Perfumes (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Arrangements For Transmission Of Measured Signals (AREA)

DK198705092A 1986-09-29 1987-09-28 Analysemetode og diagnosesæt til undersøgelse af unormal lipidmetabolisme DK173724B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/913,140 US4828986A (en)	1986-09-29	1986-09-29	Assay method and diagnostic system for determining the ratio of APO B-100 to APO A-I in a blood sample
US91314086		1986-09-29

Publications (3)

Publication Number	Publication Date
DK509287D0 DK509287D0 (da)	1987-09-28
DK509287A DK509287A (da)	1988-03-30
DK173724B1 true DK173724B1 (da)	2001-07-30

Family

ID=25432962

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198705092A DK173724B1 (da)	1986-09-29	1987-09-28	Analysemetode og diagnosesæt til undersøgelse af unormal lipidmetabolisme

Country Status (17)

Country	Link
US (1)	US4828986A (sv)
EP (1)	EP0262854B1 (sv)
JP (1)	JP2656774B2 (sv)
AT (1)	ATE85435T1 (sv)
AU (1)	AU611096B2 (sv)
CA (1)	CA1285869C (sv)
DE (1)	DE3783991T2 (sv)
DK (1)	DK173724B1 (sv)
ES (1)	ES2053555T3 (sv)
FI (1)	FI89214C (sv)
GR (1)	GR3008027T3 (sv)
IE (1)	IE60119B1 (sv)
IL (1)	IL83938A (sv)
NO (1)	NO173902C (sv)
NZ (1)	NZ221941A (sv)
PT (1)	PT85827B (sv)
ZA (1)	ZA876970B (sv)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0257778B1 (en) *	1986-08-06	1995-03-22	Scripps Clinic And Research Foundation	Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas
DE3734015A1 (de) *	1987-10-08	1989-04-20	Behringwerke Ag	Diagnostisches mittel und verfahren zur bestimmung von apolipoprotein b
AU621575B2 (en) *	1987-11-02	1992-03-19	Scripps Clinic And Research Foundation	Diagnostic methods and systems for quantifying apo ai
US5759774A (en) *	1988-05-18	1998-06-02	Cobe Laboratories, Inc.	Method of detecting circulating antibody types using dried or lyophilized cells
US5183738A (en) *	1988-09-29	1993-02-02	Japan Immuno Research Laboratories Co., Ltd.	Kit for the detection of denatured lipoproteins
US5179008A (en) *	1989-02-09	1993-01-12	Wisconsin Alumni Research Foundation	Hybridoma and monoclonal antibody to FHAP
US5168045A (en) *	1989-08-18	1992-12-01	The Scripps Research Institute	Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
US5473039A (en) *	1989-08-18	1995-12-05	The Scripps Research Institute	Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
AU662885B2 (en) *	1990-06-07	1995-09-21	Scripps Research Institute, The	APO AI polypeptides, antibodies, and immunoassays
WO1992009893A1 (en) *	1990-11-29	1992-06-11	Carbaugh John E	DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR LIPOPROTEIN(a)
DK0559795T3 (da) *	1990-11-30	1996-01-29	Monoclonetics Int	Fremgangsmåder til diagnosticering af kroniske smerter i lænderegionen og halshvrivelsøjlen
US5844097A (en) *	1990-11-30	1998-12-01	Monoclonetics International, Inc.	Methods for the diagnosis of peripheral nerve damage
US5408038A (en) *	1991-10-09	1995-04-18	The Scripps Research Institute	Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
CA2145389A1 (en) *	1992-09-24	1994-03-31	Laszlo Varady	Quantitative measurement of ldl
US6107045A (en) *	1994-06-30	2000-08-22	Oklahoma Medical Research Foundation	Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US5994061A (en) *	1995-09-29	1999-11-30	Queen's University At Kingston	DNA constructs and methods for screening for increased expression of human apo AI gene
US5741647A (en) *	1996-02-16	1998-04-21	Tam; Joseph Wing On	Flow through nucleic acid hybridisation uses thereof and a device thereof
US6248539B1 (en)	1997-09-05	2001-06-19	The Scripps Research Institute	Porous semiconductor-based optical interferometric sensor
EP0911344B1 (en)	1997-10-15	2004-03-03	Fujirebio Inc.	Anti-Apo-B-48 monoclonal antibody, hybridoma, and methods of use
AT5044U1 (de) *	2001-05-10	2002-02-25	Medsystems Diagnostics Gmbh	Quantitativer einschritt immuntest in lyophilisierter form
DE60237455D1 (de) *	2001-07-12	2010-10-07	Kyowa Medex Co Ltd	Verfahren zur quantifizierung von denaturiertem lipoprotein
US7781171B2 (en)	2003-10-15	2010-08-24	Daiichi Pure Chemicals Co., Ltd.	Mehod of pretreating sample and immunological assay method using the same
DE602004020372D1 (de)	2003-10-15	2009-05-14	Sekisui Medical Co Ltd	Verfahren zur probenvorbehandlung sowie immunologisches testverfahren unter verwendung davon
US7521248B2 (en) *	2007-04-20	2009-04-21	Atherotech, Inc.	Apo B measurement system and method
CN103946711B (zh)	2011-11-11	2018-12-04	安讯希特技术有限公司	血样本的化验方法
CN118047854B (zh) *	2024-02-26	2024-08-02	武汉鹰达生物科技有限公司	一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2061282B (en) *	1979-10-22	1983-03-30	Symphar Sa	Method for the clinical separation of a-and lipoproteins and kit for carrying out this method
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
JPS60193926A (ja) *	1984-03-15	1985-10-02	Tokyo Daigaku	単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体
JPS60253871A (ja) *	1984-05-30	1985-12-14	Nippon Koutai Kenkyusho:Kk	抗アポａ−１抗体
EP0209543A4 (en) *	1984-12-31	1989-07-11	Internat Genetic Engineering I	FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
US4677057A (en) *	1985-03-11	1987-06-30	Scripps Clinic And Research Foundation	Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins

1986
- 1986-09-29 US US06/913,140 patent/US4828986A/en not_active Expired - Lifetime
1987
- 1987-09-16 ZA ZA876970A patent/ZA876970B/xx unknown
- 1987-09-17 IL IL83938A patent/IL83938A/xx not_active IP Right Cessation
- 1987-09-22 ES ES87308392T patent/ES2053555T3/es not_active Expired - Lifetime
- 1987-09-22 AT AT87308392T patent/ATE85435T1/de not_active IP Right Cessation
- 1987-09-22 DE DE8787308392T patent/DE3783991T2/de not_active Expired - Lifetime
- 1987-09-22 EP EP87308392A patent/EP0262854B1/en not_active Expired - Lifetime
- 1987-09-25 NZ NZ221941A patent/NZ221941A/xx unknown
- 1987-09-28 CA CA000547941A patent/CA1285869C/en not_active Expired - Lifetime
- 1987-09-28 DK DK198705092A patent/DK173724B1/da not_active IP Right Cessation
- 1987-09-28 IE IE260587A patent/IE60119B1/en not_active IP Right Cessation
- 1987-09-28 FI FI874253A patent/FI89214C/sv not_active IP Right Cessation
- 1987-09-28 AU AU79028/87A patent/AU611096B2/en not_active Expired
- 1987-09-28 NO NO874056A patent/NO173902C/no unknown
- 1987-09-29 JP JP62245737A patent/JP2656774B2/ja not_active Expired - Lifetime
- 1987-09-29 PT PT85827A patent/PT85827B/pt unknown
1993
- 1993-04-30 GR GR920403215T patent/GR3008027T3/el unknown

Also Published As

Publication number	Publication date
NO874056L (no)	1988-03-30
FI89214B (fi)	1993-05-14
ZA876970B (en)	1988-03-21
ES2053555T3 (es)	1994-08-01
EP0262854A2 (en)	1988-04-06
JPS63277968A (ja)	1988-11-15
EP0262854B1 (en)	1993-02-03
DK509287D0 (da)	1987-09-28
NO173902B (no)	1993-11-08
DE3783991T2 (de)	1993-06-09
FI874253A0 (fi)	1987-09-28
JP2656774B2 (ja)	1997-09-24
EP0262854A3 (en)	1989-12-06
DE3783991D1 (de)	1993-03-18
ATE85435T1 (de)	1993-02-15
IE872605L (en)	1988-03-29
NO874056D0 (no)	1987-09-28
IL83938A0 (en)	1988-02-29
GR3008027T3 (sv)	1993-09-30
AU611096B2 (en)	1991-06-06
PT85827B (pt)	1990-08-31
FI874253L (fi)	1988-03-30
AU7902887A (en)	1988-03-31
IL83938A (en)	1991-12-15
FI89214C (sv)	1993-08-25
DK509287A (da)	1988-03-30
US4828986A (en)	1989-05-09
NO173902C (no)	1994-02-16
IE60119B1 (en)	1994-06-01
PT85827A (en)	1987-10-01
NZ221941A (en)	1989-05-29
CA1285869C (en)	1991-07-09

Publication	Publication Date	Title
DK173724B1 (da)	2001-07-30	Analysemetode og diagnosesæt til undersøgelse af unormal lipidmetabolisme
DK173174B1 (da)	2000-02-28	Monoklonale paratopiske molekyler, hybridomer, der producerer disse molekyler, og deres anvendelse til bestemmelse af apoli
AU596096B2 (en)	1990-04-26	A diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
Bouma et al.	1986	Hypobetalipoproteinemia with accumulation of an apoprotein B-like protein in intestinal cells. Immunoenzymatic and biochemical characterization of seven cases of Anderson's disease.
Angevine et al.	1966	A cold agglutinin of the IgA class
US5330910A (en)	1994-07-19	Apolipoprotein B-specific monoclonal antibodies produced by two novel hybridomas
US6830896B2 (en)	2004-12-14	Process for analyzing annexin-V in urine, and application thereof
DK171813B1 (da)	1997-06-16	Fremgangsmåde til fremstilling af partikelstabiliserede epitoper til standardisering og kontrol af immunbestemmelser, sammensætninger, der omfatter sådanne epitoper, samt immunbestemmelsessæt til måling af lipoprotein
NO328316B1 (no)	2010-01-25	Fremgangsmate for immunologisk a male humant medullasininnhold i blod og fremgangsmate for diagnostisering av multippel sklerose ved den samme.
CA1247023A (en)	1988-12-20	Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
De Bruin et al.	1990	Proteolysis of human apolipoprotein B: effect on quantitative immunoturbidimetry
Li	1992	Production, characterization, and use of monoclonal antibodies directed against bovine platelet thrombospondin

Legal Events

Date	Code	Title	Description
2001-07-30	B1	Patent granted (law 1993)
2007-10-15	PUP	Patent expired